<?xml version='1.0' encoding='utf-8'?>
<document id="27737742"><sentence text="Coupling Data Mining and Laboratory Experiments to Discover Drug Interactions Causing QT Prolongation." /><sentence text="QT interval-prolonging drug-drug interactions (QT-DDIs) may increase the risk of life-threatening arrhythmia" /><sentence text=" Despite guidelines for testing from regulatory agencies, these interactions are usually discovered after drugs are marketed and may go undiscovered for years" /><sentence text="" /><sentence text="Using a combination of adverse event reports, electronic health records (EHR), and laboratory experiments, the goal of this study was to develop a data-driven pipeline for discovering QT-DDIs" /><sentence text="" /><sentence text="1" /><sentence text="8 million adverse event reports were mined for signals indicating a QT-DDI" /><sentence text=" Using 1" /><sentence text="6 million electrocardiogram results from 380,000 patients in our institutional EHR, these putative interactions were either refuted or corroborated" /><sentence text=" In the laboratory, we used patch-clamp electrophysiology to measure the human ether-à-go-go-related gene (hERG) channel block (the primary mechanism by which drugs prolong the QT interval) to evaluate our top candidate" /><sentence text="" /><sentence text="Both direct and indirect signals in the adverse event reports provided evidence that the combination of ceftriaxone (a cephalosporin antibiotic) and lansoprazole (a proton-pump inhibitor) will prolong the QT interval"><entity charOffset="104-115" id="DDI-PubMed.27737742.s13.e0" text="ceftriaxone" /><entity charOffset="119-132" id="DDI-PubMed.27737742.s13.e1" text="cephalosporin" /><entity charOffset="149-161" id="DDI-PubMed.27737742.s13.e2" text="lansoprazole" /><pair ddi="false" e1="DDI-PubMed.27737742.s13.e0" e2="DDI-PubMed.27737742.s13.e0" /><pair ddi="false" e1="DDI-PubMed.27737742.s13.e0" e2="DDI-PubMed.27737742.s13.e1" /><pair ddi="false" e1="DDI-PubMed.27737742.s13.e0" e2="DDI-PubMed.27737742.s13.e2" /><pair ddi="false" e1="DDI-PubMed.27737742.s13.e1" e2="DDI-PubMed.27737742.s13.e1" /><pair ddi="false" e1="DDI-PubMed.27737742.s13.e1" e2="DDI-PubMed.27737742.s13.e2" /></sentence><sentence text=" In the EHR, we found that patients taking both ceftriaxone and lansoprazole had significantly longer QTc intervals (up to 12 ms in white men) and were 1"><entity charOffset="48-59" id="DDI-PubMed.27737742.s14.e0" text="ceftriaxone" /><entity charOffset="64-76" id="DDI-PubMed.27737742.s14.e1" text="lansoprazole" /><pair ddi="false" e1="DDI-PubMed.27737742.s14.e0" e2="DDI-PubMed.27737742.s14.e0" /><pair ddi="false" e1="DDI-PubMed.27737742.s14.e0" e2="DDI-PubMed.27737742.s14.e1" /></sentence><sentence text="4 times more likely to have a QTc interval above 500 ms" /><sentence text=" In the laboratory, we found that, in combination and at clinically relevant concentrations, these drugs blocked the hERG channel" /><sentence text=" As a negative control, we evaluated the combination of lansoprazole and cefuroxime (another cephalosporin), which lacked evidence of an interaction in the adverse event reports"><entity charOffset="56-68" id="DDI-PubMed.27737742.s17.e0" text="lansoprazole" /><entity charOffset="73-83" id="DDI-PubMed.27737742.s17.e1" text="cefuroxime" /><entity charOffset="93-106" id="DDI-PubMed.27737742.s17.e2" text="cephalosporin" /><pair ddi="false" e1="DDI-PubMed.27737742.s17.e0" e2="DDI-PubMed.27737742.s17.e0" /><pair ddi="false" e1="DDI-PubMed.27737742.s17.e0" e2="DDI-PubMed.27737742.s17.e1" /><pair ddi="false" e1="DDI-PubMed.27737742.s17.e0" e2="DDI-PubMed.27737742.s17.e2" /><pair ddi="false" e1="DDI-PubMed.27737742.s17.e1" e2="DDI-PubMed.27737742.s17.e1" /><pair ddi="false" e1="DDI-PubMed.27737742.s17.e1" e2="DDI-PubMed.27737742.s17.e2" /></sentence><sentence text=" We found no significant effect of this pair in either the EHR or in the electrophysiology experiments" /><sentence text=" Class effect analyses suggested this interaction was specific to lansoprazole combined with ceftriaxone but not with other cephalosporins"><entity charOffset="66-78" id="DDI-PubMed.27737742.s19.e0" text="lansoprazole" /><entity charOffset="93-104" id="DDI-PubMed.27737742.s19.e1" text="ceftriaxone" /><entity charOffset="124-138" id="DDI-PubMed.27737742.s19.e2" text="cephalosporins" /><pair ddi="false" e1="DDI-PubMed.27737742.s19.e0" e2="DDI-PubMed.27737742.s19.e0" /><pair ddi="false" e1="DDI-PubMed.27737742.s19.e0" e2="DDI-PubMed.27737742.s19.e1" /><pair ddi="false" e1="DDI-PubMed.27737742.s19.e0" e2="DDI-PubMed.27737742.s19.e2" /><pair ddi="false" e1="DDI-PubMed.27737742.s19.e1" e2="DDI-PubMed.27737742.s19.e1" /><pair ddi="false" e1="DDI-PubMed.27737742.s19.e1" e2="DDI-PubMed.27737742.s19.e2" /></sentence><sentence text="" /><sentence text="Coupling data mining and laboratory experiments is an efficient method for identifying QT-DDIs" /><sentence text=" Combination therapy of ceftriaxone and lansoprazole is associated with increased risk of acquired long QT syndrome"><entity charOffset="24-35" id="DDI-PubMed.27737742.s22.e0" text="ceftriaxone" /><entity charOffset="40-52" id="DDI-PubMed.27737742.s22.e1" text="lansoprazole" /><pair ddi="false" e1="DDI-PubMed.27737742.s22.e0" e2="DDI-PubMed.27737742.s22.e0" /><pair ddi="false" e1="DDI-PubMed.27737742.s22.e0" e2="DDI-PubMed.27737742.s22.e1" /></sentence><sentence text="" /></document>